IDEAS home Printed from https://ideas.repec.org/a/rbs/ijbrss/v11y2022i7p121-130.html
   My bibliography  Save this article

An exploratory study towards business sustainability through strategic leadership in emerging pharmaceutical business of South Africa: A case of Alpha distribution

Author

Listed:
  • Blessing Takawira

    (Graduate School of Business & Leadership, University of KwaZulu-Natal, University Rd, Westville, 3630, South Africa.)

  • Macdonald Kanyangale

    (Graduate School of Business & Leadership, University of KwaZulu-Natal, University Rd, Westville, 3630, South Africa.)

  • Emmanuel Mutambara

    (Graduate School of Business & Leadership, University of KwaZulu-Natal, University Rd, Westville, 3630, South Africa.)

Abstract

Strategic leadership is crucial in today's complex, ever-changing global economy. To achieve wholesale pharmaceutical industry goals, all strategic leaders must be proficient in strategic leadership. Successful pharmaceutical wholesalers focus on strategic planning, process simplification, culture management, and human resource development. This exploratory research examined how strategic leadership can keep a Durban pharmaceutical company competitive in a changing industry. This paper examines how a pharmaceutical company in Durban, South Africa, used strategic leadership to gain a competitive advantage. This research included ten strategic pharmaceutical leaders. Semi-structured interviews were conducted with strategic leaders. The thematic analysis showed how strategic leadership skills and responsibilities keep a company competitive. The results showed that Alpha Pharma's competitive advantage in Durban was impacted by strategic thinking, emotional intelligence, diversity management, and collective leadership. This study confirms that strategic leadership involves establishing a course of action, dealing with business complexities, advocating for a new organisational structure, shaping the company's culture, and developing its human resources. Research about strategic leadership helps pharmaceutical companies build internal capabilities and adapt to a changing market. Key Words:Strategic leadership, sustainability, competitive advantage, competencies, pharmaceutical

Suggested Citation

  • Blessing Takawira & Macdonald Kanyangale & Emmanuel Mutambara, 2022. "An exploratory study towards business sustainability through strategic leadership in emerging pharmaceutical business of South Africa: A case of Alpha distribution," International Journal of Research in Business and Social Science (2147-4478), Center for the Strategic Studies in Business and Finance, vol. 11(7), pages 121-130, October.
    • Handle: RePEc:rbs:ijbrss:v:11:y:2022:i:7:p:121-130
    DOI: 10.20525/ijrbs.v11i7.2077
    as

    Download full text from publisher

    File URL: https://www.ssbfnet.com/ojs/index.php/ijrbs/article/view/2077/1472
    Download Restriction: no
    File URL: https://doi.org/10.20525/ijrbs.v11i7.2077
    Download Restriction: no
    File URL: https://libkey.io/10.20525/ijrbs.v11i7.2077?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2016. "The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India," American Economic Review, American Economic Association, vol. 106(1), pages 99-135, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mayank Aggarwal & Anindya S. Chakrabarti & Chirantan Chatterjee, 2023. "Movies, stigma and choice: Evidence from the pharmaceutical industry," Health Economics, John Wiley & Sons, Ltd., vol. 32(5), pages 1019-1039, May.
    2. Aaron Barkley, 2023. "The Human Cost of Collusion: Health Effects of a Mexican Insulin Cartel," Journal of the European Economic Association, European Economic Association, vol. 21(5), pages 1865-1904.
    3. Heidi L. Williams, 2016. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
    4. Madan Dhanora & Ruchi Sharma & Walter G. Park, 2021. "Technological Innovations and Market Power: A Study of Indian Pharmaceutical Industry," Millennial Asia, , vol. 12(1), pages 5-34, April.
    5. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016. "Patents and the Global Diffusion of New Drugs," American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
    6. Kirill Borusyak & Xavier Jaravel & Jann Spiess, 2021. "Revisiting Event Study Designs: Robust and Efficient Estimation," Papers 2108.12419, arXiv.org, revised Jan 2024.
    7. Wang, Lucy Xiaolu, 2022. "Global drug diffusion and innovation with the medicines patent pool," Journal of Health Economics, Elsevier, vol. 85(C).
    8. Dhanora, Madan & Sharma, Ruchi & Khachoo, Qayoom, 2018. "Non-linear impact of product and process innovations on market power: A theoretical and empirical investigation," Economic Modelling, Elsevier, vol. 70(C), pages 67-77.
    9. Walker Hanlon & Taylor Jaworski, 2022. "Spillover Effects of Intellectual Property Protection in the Interwar Aircraft Industry," The Economic Journal, Royal Economic Society, vol. 132(645), pages 1824-1851.
    10. Callejas, Jerónimo & Mohapatra, Debi Prasad, 2021. "Welfare effects of public procurement of medicines: Evidence from Ecuador," International Journal of Industrial Organization, Elsevier, vol. 75(C).
    11. Kyle, Margaret K. & Ridley, David B. & Zhang, Su, 2017. "Strategic interaction among governments in the provision of a global public good," Journal of Public Economics, Elsevier, vol. 156(C), pages 185-199.
    12. de Rassenfosse, Gaétan & Grazzi, Marco & Moschella, Daniele & Pellegrino, Gabriele, 2022. "International patent protection and trade: Transaction-level evidence," European Economic Review, Elsevier, vol. 147(C).
    13. Atal, Juan Pablo & Cuesta, José Ignacio & Sæthre, Morten, 2018. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Discussion Paper Series in Economics 20/2018, Norwegian School of Economics, Department of Economics.
    14. Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.
    15. Mrityunjay Kumar & Ayesha Fatma & Nalin Bharti, 2022. "Access to Medicines and Medical Equipment during COVID-19: Searching Compatibility between the WTO and the WHO," India Quarterly: A Journal of International Affairs, , vol. 78(1), pages 68-87, March.
    16. Yoshimi Okada & Sadao Nagaoka, 2017. "Global Spread of Pharmaceutical Patent Protection: Micro Evidence from the International Equivalents of Drug Patents in Japan," Millennial Asia, , vol. 8(1), pages 26-47, April.
    17. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    18. Domini, Giacomo & Grazzi, Marco & Moschella, Daniele & Treibich, Tania, 2022. "For whom the bell tolls: The firm-level effects of automation on wage and gender inequality," Research Policy, Elsevier, vol. 51(7).
    19. Duan, Yuqi, 2021. "What is The Impact of Chinas Entry into the WTO on CO2 Emissions?," Warwick-Monash Economics Student Papers 26, Warwick Monash Economics Student Papers.
    20. Heidi L. Williams, 2017. "How Do Patents Affect Research Investments?," Annual Review of Economics, Annual Reviews, vol. 9(1), pages 441-469, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:rbs:ijbrss:v:11:y:2022:i:7:p:121-130. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Umit Hacioglu (email available below). General contact details of provider: https://edirc.repec.org/data/ssbffea.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.